Somewhat Favorable News Coverage Somewhat Unlikely to Impact Tokai Pharmaceuticals (NVUS) Share Price

News articles about Tokai Pharmaceuticals (NASDAQ:NVUS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tokai Pharmaceuticals earned a news impact score of 0.00 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.0374989999871 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Tokai Pharmaceuticals (NVUS) remained flat at $$3.81 on Tuesday. 5,300 shares of the stock were exchanged, compared to its average volume of 20,840. Tokai Pharmaceuticals has a 52 week low of $3.42 and a 52 week high of $15.12.

Tokai Pharmaceuticals (NASDAQ:NVUS) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Tokai Pharmaceuticals (NVUS) Share Price” was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://weekherald.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-tokai-pharmaceuticals-nvus-share-price.html.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Insider Buying and Selling by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply